Company* (Country,Symbol) | Company* (Country,Symbol) | Type/Product Area | Terms/Details (Month) |
|
Abgenix Inc. (ABGX) | Lexicon Genetics Inc. (LEXG) | Research collaboration/use of Abgenix's XenoMouse technology to discover antibodies to Lexicon's genomic targets | Each company will have the right to obtain exclusive commercialization rights, including sublicensing rights, for an equal number of promising antibodies; each will receive milestones and royalties on sales of antibody drugs from the collaboration that are commercialized by the other party or through a third-party collaboration (7/00) |
Abgenix Inc.(ABGX) | Immunex Corp. (IMNX) | Development and commercialization agreement/Abgenix's ABX-EGF, an anticancer monoclonal antibody to the receptor for epidermal growth factor | Immunex will make an initial license fee payment to Abgenix and a second payment upon commencement of Phase II clinical trials; development costs will be shared equally, as would any potential profits from sales of a targeted product; responsibility for product development will be shared by both companies; Abgenix will complete the ongoing Phase I trial, while both companies will share efforts in the execution of Phase II trials; Immunex will have primary responsibility for Phase III clinical trials and will market any potential product, while Abgenix will retain co-promotion rights (7/00) |
Acadia Pharmaceuticals | ArQule Inc. (ARQL) | License/serotonergic lead compounds discovered in companies' ongoing research collaboration | Acadia will obtain rights to develop and commercialize drugs based on novel leads and will pay ArQule milestones and royalties; companies will continue their pre-existing research collaboration on several other gene-derived targets (5/00) |
Affymetrix Inc. (AFFX) | Deltagen Inc. (DGEN) | Research collaboration/use of Affymetrix's GeneChip probe arrays to build and commercialize DeltaXpress databases of gene expression information based on Deltagen's knockout mouse models | Deltagen will pay annual subscription fees, pay for probe arrays and related instrumentation and software, and pay royalties to Affymetrix on database subscription fees (7/00) |
Affymetrix Inc. (AFFX) | Gene Logic Inc. (GLGC) | Technology access/Affymetrix will develop a set of custom GeneChip DNA arrays using Gene Logic's sequence information | Gene Logic will use the arrays to expand its GeneExpress database (5/00) |
Affymetrix Inc. (AFFX) | MWG-Biotech AG (Germany; Neuer Markt: NWU) |
License/certain Affymetrix intellectual property for commercializing low- and medium-density DNA arrays | MWG-Biotech has been granted a nonexclusive, worldwide, royalty-bearing license allowing the company to manufacture, use and sell low- and medium-density pre-spotted arrays; the license provides rights for the research field for gene expression with mechanically spotted arrays; Affymetrix will receive undisclosed fees and royalty payments on products sold by MWG-Biotech; MWGBiotech will cooperatively promote Affymetrix's scanner and software (6/00) |
Alkermes Inc.(ALKS) | Amylin Pharmaceuticals Inc. (AMLN) | Research and development collaboration/injectable, long-acting formulation of Amylin's AC2993 (synthetic exendin-4) using Alkermes' Medisorb delivery technology | Alkermes granted an exclusive, worldwide license for the development of injectable, sustained-release formulations of exendins, such as AC2993, and other related compounds that Amylin may develop; Alkermes will receive funding for research and development, milestones comprised of cash and warrants for Amylin common stock, and royalties and manufacturing fees for commercialized products (5/00) |
Alkermes Inc.(ALKS) | MedImmune Inc. (MEDI) | Development agreement/development of an inhalable formulation of a monoclonal antibody targeting the respiratory syncytial virus (RSV) using Alkermes' AIR pulmonary technology | MedImmune will receive an exclusive, worldwide license to products produced by the collaboration; Alkermes will receive certain initial fees, development funding, milestone payments, manufacturing fees and royalties on product sales; Alkermes is responsible for product formulation, pulmonary delivery device development and commercial supply; MedImmune is responsible for clinical development, bulk product supply, regulatory approval and worldwide marketing (6/00) |
Amarillo Biosciences Inc.(OTC BB:AMAR) | Biopharm Group International (Egypt) | Development and marketing/Amarillo's low-dose orally administered interferon alpha in conjunction with an antiviral for treatment of hepatitis C | Agreement calls for clinical co-development and marketing (5/00) |
Amarillo Biosciences Inc.(OTC BB:AMAR) | Hayashibara Biochemical Laboratories (Japan) | Expansion of development agreement/HBL's natural human interferon gamma | Expansion is to include worldwide rights for an inhalable dosage form (excluding Japan); Amarillo holds the worldwide development and distribution rights for HBL's interferon gamma when used for low-dose oral administration (6/00) |
Amarillo Biosciences Inc. (OTC BB:AMAR) | Key Oncologics Pty. Ltd. (South Africa) | Marketing/Amarillo's low-dose, orally available interferon alpha | Agreement provides Key with marketing rights in South Africa, Zimbabwe, Botswana and Namibia (5/00) |
Ambi Inc. (AMBI) | Biosynexus Inc.* | License/Ambi's nisin and lysostaphin antibacterial technologies for pharmaceuticals | Ambi will receive $1.4M up front, $14M in milestones, warrants to purchase shares of Biosynexus, royalties on commercialized products, and potential other consideration based on future transactions between Biosynexus and third parties (8/00) |
American Biogenetic Sciences Inc. (OTC BB:MABA) | Trevigen Inc.* | Research collaboration/use of ABS' antigen-free technology to produce monoclonal antibodies for control of DNA damage | ABS will receive a royalty on all commercial products developed from the collaboration and will retain manufacturing rights (5/00) |
Arena Pharmaceuticals Inc. (ARNA) | Lexicon Genetics Inc. (LEXG) | Reserach collaboration/discovery of drug candidates that target G proteincoupled receptors | Both companies will contribute equal numbers of GPCRs to be validated simultaneously by Lexicon's Seek Target Validation Program and Arena's CART technology; each will share equally in up-front fees, milestones and royalties from products developed from alliance GPCRs and will fund its own effort; the companies plan to partner the majority of candidates with third parties (8/00) |
Argonaut Technologies Inc. (AGNT) | MediChem Research Inc.* | Development collaboration/methodology that will allow researchers to speed chemical reaction optimization; methodology will combine parallel synthetic methods with statistical Design of Experiments software using MediChem's proprietary technology | Argonaut will incorporate the methodology with its existing Surveyor instrument and will distribute the integrated platform worldwide (7/00) |
Array Biopharma Inc.* | Tularik Inc. (TLRK) | Research collaboration/Array will design and synthesize a small-molecule-focused library targeting orphan nuclear receptors discovered by Tularik | Following a period of exclusivity with Tularik, Array may offer the compounds in the library to third parties (5/00) |
Array Biopharma Inc.* | Icos Corp. (ICOS) | Expansion of research collaboration/expansion based on discovery of a clinical candidate inhibitor of PDE4 | Companies entered a process and manufacturing agreement and have expanded their initial drug discovery collaboration, which focused on lead optimization for four Icos targets (8/00) |
Arrow Therapeutics plc* (UK) | Triangle Pharmaceuticals Inc. (VIRS) | Research collaboration/development of hepatitis B antivirals based on an Arrow target; Arrow will provide high throughput screening technology and a compound library, handle preclinical and clinical work | Triangle will pay an up-front fee, milestones and royalties; the deal is for two years initially, renewable for two more years, and open to further extensions after that (7/00) |
Atrix Laboratories(ATRX) | Elan Corp. plc (Ireland; NYSE:ELN) | Joint venture/development of oncology and pain management products using Atrix's BEMA and Atrigel systems and Elan's NanoCrystal technology | Elan will provide development funding, but Atrix initially will be the majority owner of the venture; Elan will make an equity investment of $5M in Atrix at a premium (6/00) |
Avigen Inc. (AVGN) | Stratagene* | License agreement/grants Stratagene worldwide exclusive rights to sell kits for making Avigen's recombinant adeno-associated virus (AAV) vectors for research purposes | Avigen will receive an up-front payment and royalties on sales of the AAV kits and other products developed by Stratagene, including genomic-based research tools, using Avigen's AAV technology; Avigen will receive rights to all AAV technologies and intellectual property developed by Stratagene (7/00) |
BioSante Pharmaceuticals Inc. (OTC BB:BTPH) | ID Biomedical Corp. (Canada; TSE:IDB) | Option license/development of BioSante's calcium phosphate nanoparticle core technology as an adjuvant in a vaccine against group A streptococcus |
BioSante will test its adjuvant and delivery system in a group A streptococcus vaccine and will formulate a second-generation vaccine using the technology and proprietary antigens from ID; ID also obtained a worldwide exclusive license to use the technology in future vaccines (6/00) |
Biosite Diagnostics Inc. (BSTE) | Medarex Inc. (MEDX) | Research collaboration/creation of Trans-Phage Technology, a high throughput method for creating fully human antibodies; the method combines Medarex's HuMAb-Mouse (for generating fully human monoclonal antibodies) with Biosite's Omniclonal phage display technology | Biosite and Medarex will offer pharmaceutical and biotechnology companies access to large volumes of high-affinity, fully human antibodies to validate genomic targets and to identify promising drug candidates; Biosite will receive research funding of $3M per year over eight years from Medarex, along with research fees, milestone payments and royalties; Biosite may also receive diagnostic rights to targets identified through the collaboration (6/00) |
Biosyntech Canada Inc. (OTCBB:BSYI) | Biomet Inc. (BMET) | Research collaboration/use of Biosyntech's BST-GEL as a carrier for growth factor and gene delivery to accelerate fresh fracture repair of bones | ND (5/00) |
BioTools Inc.* | DoubleTwist Inc.* | Software partnership/DoubleTwist's internet portal will provide BioTools' PepTool and GeneTool products for protein and genomic sequence analysis | Full versions of both software tools will be available to all registered DoubleTwist.com users without charge (5/00) |
Boston Probes Inc. | PE Biosystems Group (NYSE:PEB) | Cross-license agreement/development and commercialization of products employing peptide nucleic acid (PNA) technology for use in basic research, pharmaceutical discovery, diagnostic development, and food and environmental testing | PE Biosystems will hold a minority equity position in BPI and will be represented on the BPI board of directors; each company will have well-defined rights for its respective product offerings and for all sublicensing (6/00) |
Celera Genomics (NYSE:CRA) | Immunex Corp. (IMNX) | Database subscription/four of Celera's genomic products: the Human Genome Database, the Human Gene Index, the Drosophila Genome Database and the Mouse Genome Database | Immunex subscribed to four Celera products for five years; details ND (6/00) |
Celera Genomics(NYSE:CRA) | Life Technogies Inc. (OTC BB:LTEK) | Development collaboration/development of a large collection of clones containing human full-length genes and the corresponding DNA sequences of such genes | Gene sequence information will be used to annotate Celera's Human Genome Database, and the clones would be available from Life Technologies through an active link within the database; clones containing proprietary genes could be available to researchers in both academia and for-profit entities; the two companies will share revenues generated by the output resulting from this agreement, including sales of clones and licensing of intellectual property (7/00) |
Chemdex Corp. (CMDX) | DoubleTwist Inc.* | E-commerce agreement/three-year partnership to integrate the Chemdex e-commerce solution into the DoubleTwist.com genomic research portal |
Chemdex will make a strategic equity investment in DoubleTwist and will be the preferred provider of e-commerce services for DoubleTwist and its customers; the agreement simplifiesprocurement for DoubleTwist.com users who will automatically be notified when the supplies relevant to their online genomic research are available for purchase throught the Chemdex marketplace (5/00) |
Chiron Corp.(CHIR) | Biomira Inc. (Canada; BIOM) | Option exercise/Theratope therapeutic vaccine for metastatic breast cancer | Biomira will exercise its right to acquire Chiron's remaining rights to Theratope under a 1997 collaboration; Biomira will provide compensation to Chiron of $2.25M; upon U.S. regulatory approval and commercialization, Biomira will make one final payment to Chiron of $3.25M (6/00) |
Chrysalis Biotechnology Inc.* | OrthoLogic Corp. (OLGC) | Expansion of 1/99 license agreement/U.S. rights to orthopedic indications for Chrysalin, a synthetic 23-amino-acid peptide corresponding to a portion of thrombin | OrthoLogic will pay Chrysalis Biotechnology a one-time license fee of $2M to extend rights worldwide; OrthoLogic will pay certain milestone payments and royalty fees based upon the products developed and achievement of commercial success (7/00) |
Coelacanth Corp.* | Microcide Pharmaceuticals Inc. (MCDE) | Research agreement/Coelacanth will provide novel libraries of compounds for screening in a broad range of Microcide assays directed at the identification of innovative antiviral, antifungal and antibacterial therapeutic agents |
Microcide will have the worldwide rights to develop compounds that emerge from the agreement; Coelacanth will receive milestone payments during the drug development and approval process and royalties on product sales (6/00) |
Connetics Corp. | InterMune PharmaceuticalsInc. (ITMN) | Acquisition of rights/rights to Actimmune (interferon gamma-1b) revenue;Actimmune is FDA-approved for chronic granulomatous disease and osteopetrosis | InterMune paid $5.2M for the remaining U.S. rights it did not own; prior to the trans-(CNCT) action, Connetics had the right to recognize Actimmune revenue and related expenses associated with about the first $6.5M in U.S. sales in 2000 and 2001 (6/00) |
Cortech Inc.(CRTQ) | United Therapeutics Corp.(UTHR) | License termination/UT-77, a serine elastase inhibitor based on preclinicalresults and Phase II testing | ND (6/00) |
Cytovax Biotechnologies Inc.* (Canada) | BioChem Pharma Inc. (Canada; BCHE) | License and development/vaccine against Pseudomonas aeruginosa; collaboration includes a monoclonal antibody that could be used as a preventive or therapeutic agent |
BioChem will commit research funding and expertise to the alliance and will purchase an equity stake in Cytovia, which also will receive development milestone payments and royalties; BioChem receives worldwide rights to develop, manufacture and market the products (6/00) |
DepoMed Inc.(AMEX:DMI) | AVI BioPharma Inc. (AVII) | Development collaboration/feasibility of controlled oral delivery of AVI's proprietary Neugene antisense agents | Collaboration will involve developing oral formulations of one or more of AVI's products; scientists at AVI and DepoMed will work together to study the feasibility of oral drug into the upper gastrointestinal tract (6/00) |
Diaclone SA (subsidiary of the Biotest Group; France) | Nexell Therapeutics Inc. (NEXL) use in ex vivo cell therapy (previous rights) | Conversion of 1/00 license agreement/Nexell Therapeutics gains exclusive rights to six monoclonal antibodies for agreement conveyed non-exclusive | The agreement also gives Nexell Therapeutics right of first refusal for potential in vivo applications of the antibodies and access to both finished product and master cell lines necessary to produce the six monoclonal antibodies; the portfolio includes CD138, useful for purging myeloma cells; CD25, a T-cell activation marker that may facilitate the removal of alloreactive cells from a stem-cell graft prior to transplant; CD56 and CD16, markers for NK (natural killer) cells; CD14, a monocyte marker; and CD4, the marker for T-helper cells (6/00) |
Diversa Corp. (DVSA) | Invitrogen Corp. (IVGN) | License agreement/Invitrogen gains exclusive rights to commercialize three of Diversa's thermostable DNA-modifying enzymes for the molecular biology research market | Diversa will receive royalties on sales of the enzymes, while maintaining rights to the diagnostics market (7/00) |
DNAPrint genomics(Pink Sheets:DNAP) | Geospiza Inc.* | Beta testing/Geospiza's DNA sequence information management system for standard DNA sequencing files | DNAPrint will conduct beta testing of the system under extendable agreement (8/00) |
Enchira Biotechnology Corp. (ENBC) | Genencor International Inc. (GCOR) | License/use of Enchira's RACHITT system to develop genebased products for the cleaning, textiles, grain processing, animal feed and food ingredients industries | Agreement includes up-front licensing fees, milestones and royalties (5/00) |
EraGen Biosciences* | TimeLogic Corp.* | Marketing and development collaboration/collaboration to deliver tools for managing high-throughput sequence analysis by using EraGen's proprietary gene databases and Time Logics' high-speed computing | Both companies will promote each other's technologies through the creation of a channel partnership (7/00) |
FibroGen Inc.* | ZymoGenetics Inc. (subsidiary of new tissue sealant products for of Novo Nordisk A/S [Denmark;NYSE:NVO]) | Research collaboration/development wound management | FibroGen will pair its recombinant human Type II collagen with ZymoGenetics' recombinant human thrombin, a therapeutic protein critical for the clotting process; the companies plan to develop and potentially commercialize novel wound repair products (7/00) |
GeneEd Inc.* | Incyte Genomics Inc. (INCY) | Education/development of genomics education programs linked to Incyte's online database products | Incyte will make an equity investment in GeneEd (5/00) |
Gene Logic Inc. (GLGC) | Life Technologies Inc. (OTC BB: LTEK) | Development collaboration/fully sequence and patent the large number of human disease and predictive toxicology genes identified using Gene Logic's GeneExpress 2000 Suite of databases | Agreement provides for appropriate sharing between the two companies of revenues generated by outputs resulting from the collaboration, including sales of clones and databases, and licensing of intellectual property; as genes are identified they will be isolated by Life Technologies and sequenced and patented by Gene Logic (6/00) |
Gene Logic Inc. (GLGC) | Psychiatric Genomics Inc.* | Database subscription/Psychiatric subscribed to a portion of Gene Logic's database system focusing on central nervous system samples | ND (6/00) |
Genaissance Pharmaceuticals Inc. (GNSC) | Visible Genetics Inc. (VGIN) | Expansion of 1996 license agreement/includes research and diagnostic applications in all areas of sequencebased DNA diagnostic testing | VGI has the right to sublicense the technology to third parties; the agreement covers the use of single-tube, single-step DNA sequencing technology, called CAS, covered by US Patent No. 5,427,911 (6/00) |
Genentech Inc.(NYSE:DNA) | InterMune Pharmaceuticals Inc. (ITMN) | Acquisition of rights/broad range of indications of Actimmune in Canada, including chronic granulomatous disease, osteopetrosis, idiopathic pulmonary fibrosis and infectious diseases | InterMune will pay royalties on Canadian sales (8/00) |
Genomica Corp.* | PE Biosystems Group (NYSE:PEB) | Development and reseller agreement/Genomica's genotyping analysis software, Genomica LinkMapper | PE Biosystems will co-market and exclusively distribute LinkMapper with its genotyping instruments and software (5/00) |
Genomics Collaborative Inc.* | Qiagen Genomics Inc.(subsidiary of Qiagen NV [the Netherlands; QGENF]) | Development collaboration/development of an integrated solution combining GCI's sample repository and database services with Qiagen's single nucleotide polymorphism genotyping services | ND (7/00) |
Genzyme Molecular Oncology(GZMO) | NeuralStem Biopharmaceuticals Ltd.* | License/Genzyme's SAGE (Serial Analysis of Gene Expression) genomics technology for evaluation of global gene expression from NeuralStem's human central nervous system stem cells | Genzyme Molecular Oncology will receive an up-front payment and additional fees related to the creation of SAGE data by NeuralStem and transfer of NeuralStem SAGE data to third parties; NeuralStem has an option to extend the SAGE license for up to five years (7/00) |
Genzyme Molecular Oncology(GZMO) | Affymetrix Inc. (AFFX) | License agreement/Genzyme Molecular exclusively licensed certain highdensity DNA array diagnostic and research rights related to the p53 gene to Affymetrix for use in its GeneChip arrays | Genzyme Molecular Oncology will receive from Affymetrix an up-front payment, milestones and minimum royalties on the sale of future GeneChip products that utilize the p53 gene; the license will allow GeneChip array customers to conduct microarray-p53 based tests without seeking an additional license from Genzyme (6/00) |
Genzyme Molecular Oncology (GZMO) |
Medical Molecular Research Cologne (Germany) | License agreement/Genzyme's SAGE (Serial Analysis of Gene Expression) technology | Medical Molecular Research will make the SAGE techology available to customers in Europe and will offer a complete range of SAGE services, including RNA preparation, library construction, sequencing of SAGE transcripts, bioinformatics analysis and target validation(6/00) |
Genzyme Transgenics Inc. (GZTC) | Abgenix Inc.(ABGX) | Production agreement/Genzyme Transgenics will develop transgenic goats that express the therapeutic antibody ABX-IL8 in their milk | Genzyme Transgenics will receive fees and milestones (5/00) |
Geron Corp. (GERN) | Celera Genomics (NYSE:CRA) | Research collaboration/combines Geron's expertise in human pluripotent stem cell biology with Celera's comprehensive sequencing information and gene discovery capabilities | Celera and Geron will work together to uncover important discoveries pertaining to the use and/or function of genes involved in human cell differentiation;Geron will develop and commercialize a number of small-molecule drug, protein therapeutic, cell- and gene-therapy products and prenatal diagnostics; Celera will use the information to enhance the annotation of the human genome and develop and commercialize probe sets for gene expression analysis; Celera and Geron will license to third parties certain intellectual property to develop other products (6/00) |
Geron Corp. (GERN) | Modex Therapeutics SA (France) | License/use of Geron's telomerase technology in Modex's encapsulated cell therapy system | Geron and Modex will share all income that Modex receives for products developed and commercialized under the license (5/00) |
Heavenly-Door.com Inc.(HVDC) | Interneuron Pharmaceuticals Inc. (IPIC) | Development and commercialization contract/HeavenlyDoor.com's PRO 2000, a candidate topical microbicide that has been shown to prevent infection by HIV and other sexually transmitted pathogens | Interneuron gains exclusive worldwide rights to PRO 2000 in exchange for an up-front license fee, clinical trial milestone payments and royalties on net sales; Interneuron is responsible for all remaining preclinical development, clinical testing, regulatory review and commercialization activities in connection with PRO 2000 (6/00) |
hte GmbH*(Germany) | Molecular Simulations Inc. (subsidiary of Pharmacopeia Inc. [PCOP]) | Development collaboration/use of MSI's informatics expertise to develop software for hte's high-throughput experimentation products; hte gains access to MSI's combinatorial chemistry and materials simulation software in support of its external and internal research projects | MSI will distribute the software modules developed in the collaboration (5/00) |
Hyseq Inc.(HYSQ) | Chiron Corp.(CHIR) | Extension of research collaboration/discovery of genes for use in development of solid-tumor cancer therapeutics,diagnostic molecules and vaccines | Two-year extension (5/00) |
Ibis Therapeutics(division of Isis Pharmaceuticals Inc. [ISIP]) | Agouron Pharmaceuticals Inc. (subsidiary of Pfizer Inc.[NYSE:PFE]) | Development agreement/discovery and development of small-molecule drugs against certain RNA targets | The collaboration will focus on discovering drugs that bind to RNA using Ibis' expertise in small-molecule drug discovery; Agouron will fund collaborative research, pay an up-front technology access fee and make milestone payments totaling $37M for the first product; Agouron will develop and commercialize drugs discovered by the collaboration and will pay Isis royalties on sales (6/00) |
ID Biomedical Corp.(Canada; IDBE) | DiscoveRx Corp.* | License option/DiscoveRx will explore the combination of ID's Cycling Probe Technology with its own enzyme fragmentation technology | ID received an equity stake in DiscoveRx; in exchange for an 18-month option to obtain a worldwide, non-exclusive license; the royalty bearing license, if obtained, will require an additional payment of $5M (7/00) |
ID Biomedical Corp.(Canada; IDBE) | PE Biosystems Group(NYSE:PEB) | License agreement/ID Biomedical's intellectual property for Cycling Probe Technology | The license grants PE Biosystems access to ID Biomedical's intellectual property concerning its Cycling Probe Technology; PE will pay ID Biomedical royalties based on future product sales, as well as an up-front license fee of $5M (6/00) |
ImmunoGen Inc. (IMGN) | British Biotech plc (UK; LSE:BBG) | Development and marketing agreement/ImmunoGen's huN901-DMI tumor-activated prodrug for treatment of small-cell lung cancer | British Biotech gains an exclusive right to develop and commercialize huN901-DM1 in the European Union and Japan and will pay an up-front fee of $1.5M for those rights (5/00) |
ImmunoGen Inc.(IMGN) | Genentech Inc. (NYSE:DNA) | Research collaboration/use of ImmunoGen's maytansinoid tumor-activated prodrug technology with Genentech antibodies | Five-year agreement under which Genentech will provide an up-front technology access fee of $3M and potential milestones of nearly $40M per antigen target, plus royalties on sales of resulting products; Genentech is responsible for manufacturing, product development and marketing; ImmunoGen will be reimbursed for any preclinical materials that it makes under the agreement; the agreement can be renewed for one three-year period for an additional technology access fee; agreement is the second between the two companies; the first centered on development of a TAP conjugate version of Genentech's Herceptin (5/00) |
Incyte Genomics Inc.(INCY) | Elitra Pharmaceuticals Inc.* | License/use of Incyte's PathoSeq microbial sequence database as a platform for functional genomics programs | In addition to internal use, Elitra gains the right to sell the database to third parties incollaboration with Incyte; Incyte will receive an undisclosed equity position in Elitra(7/00) |
InKine Pharmaceutical Co.(INKP) | Innovex (unit of Quintiles Transnational Corp. [QTRN]) | Contract sales and marketing/Innovex will launch and promote Diacol (under FDA review) for cleansing of the bowel prior to diagnostic procedures such as colonoscopy | InKine retains rights and control of the product (5/00) |
Intellivax International Inc.* | Active Biotech AB (Sweden; ACTIB) | Development collaboration/aimed at developing a vaccine for prevention of infections with Group A, B-hemolytic streptococci (GAS) | The initial collaboration will strive to prove the feasibility of the vaccine; Intellivax will couple its proteosome delivery platform with Active Biotech's GAS antigen to create a novel nasal spray vaccine (6/00) |
Invitrogen Corp.(IVGN) | Affymetrix Inc. (AFFX) | Development agreement/development and marketing of new software for microarray analysis | Invitrogen has agreed to adapt its Pathways microarray analysis software for use in analyzing images of spotted arrays generated with the Affymetrix's 417 Arrayer and scanned with the 418 Array Scanner (6/00) |
Karo Bio USA (unit of Karo Bio AB [Sweden;SSE:KARO]) | GPC Biotech AG (Germany;Neuer Markt:GPC) | Development collaboration/development of a new generation of broadspectrum antibiotics, based on up to 15 of GPC's genomics-derived antibacterial targets; Karo Bio USA is developing high-throughput screening assays | GPC is funding development of assays and will pay Karo Bio USA royalties on compound development or out-licensing by GPC Biotech; commercialization rights are retained by GPC Biotech; Karo Bio has the potential to obtain access to targets that GPC Biotech does not advance (6/00) |
Large Scale Proteomics Corp. (subsidiary of Large Scale Biology Corp. [LSBC]) | Biosite Diagnostics Inc. (BSTE) | Research collaboration/use of Large Scale's proteomic discovery technologies to identify targets from Biosite's patient samples | Biosite will retain target rights for development and commercialization of invitro diagnostics resulting from the alliance; Large Scale will retain target rights for other potential therapeutic and diagnostic uses; companies will share revenues from resulting products (5/00) |
Lexicon Genetics Inc.(LEXG) | Millennium Pharmaceuticals Inc. (MLNM) | Expansion of 7/99 research collaboration/use of Lexicon's knockout mouse technology to create knockouts based on Millennium targets | Agreement triples the size of the initial numbers of mouse models Lexicon will generate, and commits Millennium to obtain certain numbers of knockout mice from Lexicon during each year of the collaboration (6/00) |
Lorus Therapeutics Inc. (Canada; OTC BB:LORFF) | AVI BioPharma Inc. (AVII) | Research collaboration/evaluation and co-development of antisense drug therapies for cancer and infectious diseases; AVI will contribute its Neugene-based antisense backbone; Lorus will contribute cancer and infectious disease targets and will spearhead the collaborative research program by performing molecular, cell and animal biology experiments | Each company will retain an ownership interest in any jointly developed compound, and drugs discovered together may also be developed independently with royalty payments to the other party (7/00) |
Luminex Corp. (LMNX) | Orchid BioSciences Inc.(ORCH) | Development collaboration/development of an affordable, rapid-throughput system for conducting single nucleotide polymorphism (SNP) scoring | The new SNPstream will use Orchid's proprietary line of SNPware reagent kits and is based on Luminex's open-platform LabMAP system; Orchid will market the product line (5/00) |
Lynx Therapeutics Inc. (LYNX) | Hybrigenics SA* (France) | Research collaboration/discovery of expressed genes and protein interactions and pathways in human obesity | Companies said they will jointly exploit opportunities arising from the data (5/00) |
Magainin Pharmaceuticals Inc.(MAGN) | Genentech Inc. (NYSE:DNA) | Development collaboration/Magainin's antibody to interleukin-9 (a potential asthma treatment), with options for other products | Genentech will make a $5.5M up-front equity purchase, plus provide up to $60M in milestones and development fuding for the first product; additional products could generate further milestones and development support (5/00) |
Maxim Pharmaceuticals Inc. (MAXM) | BioChem Pharma Inc. (Canada; BCHE) | License/molecules capable of inducing cancer cells to die by activating the caspase enzyme system and triggering apoptosis | Companies will collaborate on lead optimization, after which BioChem will take over the clinical development of any drugs; BioChem will provide Maxim licensing fees, research support and milestones of up to $55M (7/00) |
Medarex Inc. (MEDX) | Centocor Inc. (subsidiary of Johnson & Johnson [NYSE:JNJ]) | Research collaboration/access to Medarex's HuMAb-Mouse technology for making fully human monoclonal antibodies | Medarex will receive technology access fees, and could also receive license fees, milestones and royalties on product sales (5/00) |
Medarex Inc. (MEDX) | Corixa Corp. (CRXA) | Development collaboration/use of Medarex's HuMAb-Mouse technology to generate fully human monoclonal antibodies against selected targets from Corixa's library of autoimmune disease, cancer and infectious disease antigens | Corixa and Medarex will hold a closed auction between the two parties for rights to develop the specific antibody-based product when antibodies are jointly determined to be worthy of clinical investigation; the company with the winning bid will pay the bid amount in cash to the other company and will be responsible for all product development and commercialization expenses and decisions; the other company will receive future product development milestone payments and royalties on future product sales (6/00) |
Medarex Inc. (MEDX) | MedImmune Inc. (MEDI) | Development agreement/use of Medarex's HuMAb-Mouse technology to generate fully human monoclonal antibodies to MedImmune antigens | MedImmune receives an exclusive, worldwide license for the use of Medarex's HuMAb-Mouse technology for the development of antibodies against respiratory syncytial virus (RSV) and an option to further license the use of this technology for additional antigens; Medarex receives technology access fees and could also receive license and milestone payments, as well as royalties on product sales (6/00) |
Meditech Pharmaceuticals Inc. (OTC BB: MDCH) | Immune Network Research Ltd. (CDNX:IMM) | License/Meditech's MTCH-24, an over-the-counter herpes simplex medication, and Viraplex, a cancer therapy | Immune Network exercised an option to a worldwide exclusive license (excluding the U.S.) and paid a licensing fee of $0.1M (5/00) |
MethylGene Inc.* (Canada) | MGI Pharma Inc. (MOGN) | Development agreement/Methyl-Gene's MG98 mRNA inhibitor and small-molecule DNA methyltransferase inhibitors for cancer | MGI will make an initial cash payment to MethylGene, and will pay milestones and royalties on sales; MethylGene retains a copromotion right in North America and all rights outside North America; the initial and milestone payments could total approximately $16M for each of the two development programs; MGI will invest an additional $6.8M in MethylGene equity (8/00) |
MicroMed Technology Inc.* | Chrysalis Vascular Technologies (unit of - Chrysalis BioTechnology Inc.*) | Evaluation agreement/evaluation of the effectiveness of Chrysalin, a synthetic-version of a portion of thrombin, in promoting regeneration of blood vessels in the heart | Upon conclusion of this evaluation, MicroMed will have the exclusive option to license Chrysalin worldwide for myocardial revascularization (7/00) |
Millennium Predictive Medicine Inc. (unit of Millennium Pharmaceuticals Inc. [MLNM]) | Becton Dickinson and Co. (NYSE:BDX) | License/use of Millennium markers to develop colon cancer diagnositcs | Becton Dickinson paid a licensing fee for certain markers and related intellectual property and has an option for a commercial license (7/00) |
Molecular Biosystems Inc. (MBIO) | Genta Inc. (GNTA) | License/broad portfolio of MBI patents and technology that relate to antisense for therapeutic and diagnostic applications | The agreement includes grants of both exclusive and non-exclusive rights to Genta from MBI on a royalty-free basis in return for cash and shares of Genta common stock (6/00) |
Morphosys AG (Germany; Neuer Markt: MORG) | Eos Biotechnology Inc.* | Research collaboration/MorphoSys' HuCAL (Human Combinatorial Antibody Library) technology for antibody generation | Eos will pay technology license fees to MorphoSys as well as make milestone and royalty payments on any antibody therapeutics; Eos has an option to develop certain antibodies as therapeutics (6/00) |
Nabi (NABI) | Collaborative BioAlliance Inc. (affiliate of The Collaborative Group Ltd.) | Production and supply agreement/Nabi StaphVax (Staphylococcus aureus Type 5 and Type 8 Capsular Polysaccharide Conjugate Vaccine) at CBA's cGMP bio-manufacturing facility in Smithfield, R.I. | ND (5/00) |
NeoRx Inc. (NERX) | Nexell Therapeutics Inc. (NEXL) | License/in vitro diagnostic applications of NRLU-5 (also referred to as the Pan-05 antibody, a cell surface marker common to many tumor types | Nexell obtains a 10-year exclusive license for all in vitro diagnostic applications of the antibody (8/00) |
NeuralStem BioPharmaceuticals Ltd.* | Gene Logic Inc. (GLGC) | License and database access/Gene Logic licensed NeuralStem's human central nervous system stem cell technology for gene expression, and NeuralStem puchased a module of Gene Logic's GeneExpress database | Gene Logic made an equity investment in NeuralStem, which will also make its CNS stem cell lines available to Gene Logic customers for discovery efforts and follow-on screening (5/00) |
Neuronyx Inc.* | Neose Technologies Inc. (NTEC) | Research and development collaboration/discovery and development of drugs for the treatment of Parkinson's disease and other neurological diseases | Neose made an investment in convertible preferred stock of Neuronyx; Neuronyx will focus on preclinical and clinical development of the compounds, and Neose will focus on the synthesis and manufacturing scale-up of targeted compounds using its proprietary technologies for carbohydrate synthesis; Neose and Neuronyx will share in any financial benefit of the collaboration (6/00) |
NPS Allelix (subsidiary of NPS Pharmaceuticals Inc. [NPSP]) | ICAgen Inc.* | License/NPS Allelix's nervous system-specific sodium channel gene technology | ND (8/00) |
NsGene A/S* (Denmark) | Biogen Inc. (BGEN) | Research and development agreement/research and potential development and commercialization of of products based on Neublastin, a novel neurotrophic protein | Biogen has the rights to pursue research, development and commercialization of therapies based on Neublastin for indications outside the central nervous system; if a product based on Neublastin is successfully developed and commercialized by Biogen, NsGene may receive royalties, as well as fees and milestone payments totaling over $20M; NsGene retains the rights to develop Neublastin for the treatment of diseases of the nervous system, with the exception of multiple sclerosis (6/00) |
Ontogeny Inc.* (now merged into Curis Inc. [CRIS]) | Biogen Inc. (BGEN) | Return of rights under 7/96 agreement/Ontogeny's hedgehog protein technology for inducing formation or regeneration of tissues | Biogen has elected to return to Ontogeny the rights from the 7/96 agreement to develop and commercialize hedgehog protein products following a portfolio review (7/00) |
Orchid BioSciences Inc. (ORCH) | Amersham Pharmacia Biotech (jointly owned by Nycomed Amersham plc [UK; NYSE: NYE] and Pharmacia Corp. [NYSE: PHA]) | License/Orchid's SNP-IT single-base primer extension technology for single nucleotide polymorphism applications | Amersham will produce and sell reagent kits and software incorporating Orchid's technology under the brand name SNuPe (6/00) |
Orchid BioSciences Inc. (ORCH) | Millennium Pharmaceuticals Inc. (MLNM) | Service agreement/Orchid will score single nucleotide polymorphisms on samples provided by Millennium | ND (7/00) |
Orchid BioSciences Inc. (ORCH) | PE Biosystems Group (NYSE:PEB) | License/use of Orchid's SNP-IT single-base primer extension technology for single nucleotide polymorphism analysis | PE will use the technology in its ABI Prism reagent kits, including SNaPshot ddNTP Primer Extension kits (6/00) |
PE Biosystems Group (NYSE:PEB) | Cepheid (CPHD) | License/manufacture and sale of thermal cyclers for use in the polymerase chain reaction process | License agreement grants rights under both PCR process patents and PE's amplification system patent regarding thermal cyclers and applies to Cepheid's family of I-CORE systems (5/00) |
Pharsight Corp. (PHST) | Guilford Pharmaceuticals Inc. (GLFD) | Technology collaboration/companies will deploy Pharsight's software, methodologies and consulting services to accelerate Guilford's clinical development programs | Three-year agreement (5/00) |
PPD Discovery (subsidiary of PPD Inc. [PPDI]) | Agouron Pharmaceuticals Inc. (wholly owned subsidiary of Pfizer Inc. [NYSE:PFE]) | Research agreement/alliance to identify new targets for selectively eradicating cancer cells; PPD Discovery's proprietary functional genomics platform, the GSX System, will be used to perform high-throughput genome-wide screening for Genetic Suppressor Elements (GSEs) capable of inducing programmed death of tumor cells | Agouron will provide an up-front payment and support research at PPD Discovery's genomics facility in Menlo Park, Calif; PPD Discovery will receive research and development milestone payments and royalties on sales of Agouron's products; PPD Discovery will retain certain rights to pharmacogenomic and diagnostic applications and products, with Agouron receiving royalties on sales of any diagnostic and pharmacogenomic products resulting from the collaboration (6/00) |
PPGx Inc. (joint venture of PPD Inc. [PPDI] and Axys Pharmaceuticals Inc. [AXPH]) | Spotfire* | Bioinformatics/integration of PPGx's advanced pharmacogenomics data warehouse and information mining product, GeneTrials, with Spotfire's decision analytics protal, Spotfire.net | ND (5/00) |
Progen Industries Ltd. (Australia; PGLAF) | Medigen Biotechnology Corp. (Taiwan) | Development collaboraiton/Progen's PI-88 for the potential treatment of cancer and cardiovascular disease | MBC will fund and conduct, at no cost to Progen, several trials; MBC will be entitled to receive 15% of Progen's future PI-88 revenues generated from cancer and cardiovascular disease and MBC has the right to negotiate the funding and conduct of several Phase III clinical trials in the diseases; Progen will supply PI-88, technical expertise and technical know-how to assist MBC in establishing a cGMP-compliant pharmaceutical manufacturing facility in Taiwan (6/00) |
Proligo LLC* | Inex Pharmaceuticals Corp. (Canada; TSE:IEX) | Manufacturing agreement/Proligo will contribute manufacturing, management and marketing services, and Inex will contribute intellectual property and patents; the compounds to be manufactured are phosphorothioate-containing nucleic acids that are capable of inhibiting the production of disease-causing proteins | The two parties will receive a share of revenues based upon their respective contributions (5/00) |
Proteome Inc.* | DoubleTwist Inc.* | Database agreement/provide data from Proteome's BioKnowledge Library through the genomic research portal DoubleTwist.com | DoubleTwist will integrate three model organism database volumes of the Bio-Knowledge Library; Proteome and DoubleTwist will share revenues generated by sales of information based on Proteome's contribution to the portal (6/00) |
RxKinetix Inc.* | Elan Corp. plc (Ireland; NYSE:ELN) | Joint venture/development of compound formulations for the treatment of oral mucositis | Initial terms of the agreement call for a three-year, extendible research and development program; each company is contributing technology; Elan will make a $2.5M equity investment in RxKinetix; the R&D program will be jointly funded; Elan will also subscribe to a convertible note (5/00) |
Sequenom Inc. (SQNM) | Genaissance Pharmaceuticals Inc. (GNSC) | Technology collaboration/use of Sequenom's MassARRAY system as the platform for Genaissance's high-throughput haplotyping facility | Agreement follows an initial MassARRAY system placement at Genaissance, which will now purchase at least two additional units; Sequenom will develop assays for Genaissance's HAP markers (5/00) |
Sequenom Inc. (SQNM) | Metabion GmbH* (Germany) | Technology sale and supply agreement/Sequenom's MassARRAY technology | Metabion will use Sequenom's MassARRAY technology to monitor the quality of Metabion's high-volume oligonucleotide production while providing Sequenom with a reliable and consistent source for oligonucleotides (6/00) |
Techniclone Corp. (TCLN) | Oxigene Inc. (OXGN) | Joint venture/development of vascular targeting technologies | Oxigene will spend up to $20M to fund development expenses at the venture, Arcus Therapeutics LLC; subsequent costs will be split equally; in addition, Oxigene paid a $1M up-front licensing fee and will purchase $2M of Techniclone's common stock at the current market price; Oxigene will also pay another $1M in cash and buy $1M in Techniclone stock upon filing of an IND for the first clinical candidate; Arcus plans to sublicense the technology to other companies for non-conflicting applications; Techniclone will receive 75% of such income until it receives $10M; thereafter, licensing fees will be shared 50-50; the companies will share any royalties or profits equally (5/00) |
Techniclone Corp. (TCLN) | Scotia Pharmaceuticals Ltd. (UK; LSE: SOH) | License/segment of Techniclone's Vascular Targeting Agent technology, specifically related to applications of photodynamic therapy | Techniclone will receive a licensing fee, milestones (as much as $7M) and royalties upon commercialization (8/1) |
Texas Biotechnology Corp. (AMEX:TXB) | Icos Corp. (ICOS) | Joint venture/development of Texas Biotech's endothelin-A receptor antagonists, such as sitaxsentan, which is nearing a Phase IIb/III trial in pulmonary hypertension | Both companies will equally fund the cost of research and development of sitaxsentan in chronic heart failure, and explore applications for second-generation endothelin antagonist compounds, commercialize resulting products and share equally in the profits worldwide; Icos will make milestone payments to Texas Biotechnology that could be as much as $55.5M for the development and commercialization of products resulting from the collaboration (6/00) |
Third Wave Technologies Inc.* | Specialty Laboratories* | Development collaboration/development of new applications for Third Wave's proprietary Invader technology platform | ND (7/00) |
Tolerance Therapeutics LLC* | Repligen Corp. (RGEN) | Acquisition of patent rights/use of CTLA4-Ig, a derivative of a natural immune cell protein capable of blocking immune responses, in immune-based diseases and organ transplantation | ND (5/00) |
Transgene (France; TRGNY) | IntroGene B.V. (the Netherlands) | License agreement/collaboration in the field of complementation cell lines for commercial production of adenoviral vectors | Agreement provides for non-exclusive cross-licensing of certain intellectual property rights and for the joint development and marketing of a new generation of IntroGene's proprietary PER.C6 cell line (6/00) |
United Therapeutics Corp. (UTHR) | Nova-Tex Ltd.* | Distribution agreement/United Theraeutics' subcutaneous prostacyclin therapy, Uniprost | Strategic alliance for the distribution of Uniprost in Israel (6/00)< /TD> |
UroCor Inc. (UCOR) | Immunex Corp. (IMNX) | License agreement/UroCor's cancer-derived antigens | Immunex will pay an initial license fee, plus potential milestone and royalties, and will be responsible for all R&D and potential commercialization costs of any approved therapeutic antibodies against licensed UroCor target antigens (7/00) |
UroGenesys Inc.* | Genentech Inc. (NYSE:DNA) | License/development of antibody-based therapeutics for cancer using UroGenesys' Prostate Stem Cell Antigen (PSCA) as a target antigen | The license covers patent rights to PSCA as a target for antibody therapy in any cancer indication, as well as a panel of monoclonal antibodies; UroGenesys could receive milestone and other payments totaling $33M, in addition to royalties on product sales (7/00) |
Variagenics Inc. (VGNX) | Waters Corp. (NYSE:WAT) | Development and commercialization agreement/NuCleave genetic variance reagent kits for use in the clinical development of pharmaceuticals | Variagenics will receive $10.5M in equity and technology transfer payments, and up to $4M in milestone payments; Waters will pay royalties on NuCleave reagent kit net sales (6/00) |
Vysis Inc. (VYSI) | Genentech Inc. (NYSE:DNA) | Development and marketing collaboration/use of Vysis' PathyVysion HER2 test kit in assessing patients for whom Genentech's Herceptin is being considered; test uses fluorescence in situhybridization to detect HER2 | Companies will make a coordinated FDA submission and collaboration may extend to future clinical studies (5/00) |
Xoma Ltd. (XOMA) | Allergan Inc. (NYSE:AGN) | Expansion of 6/99 development collaboration/all ophthalmic anti-infective formulations, including stand-alone formulations, of Xoma's recombinant bactericidal/permeability-increasing protein | Previous $11M agreement included antibiotics combinations to treat bacterial eye infections; amended agreement calls for additional milestones (5/00) |
Xoma Ltd. (XOMA) | Celltech Therapeutics Ltd. (subsidiary of Celltech plc [UK; LSE:CTP]) | License/use of Xoma's bacterial cell expression systems for pharmaceutical production | Celltech gains a non-exclusive license to the technology; Xoma's license terms typically include up-front fees, milestone payments and royalties on sales; Celltech agreement is a cross-license that allows Xoma to use Celltech's expression technologies and settles all patent opposition proceedings between the companies (5/00) |
Xoma Ltd. (XOMA) | ZymoGenetics Inc. (unit of Novo Nordisk A/S [Denmark]) | License/use of Xoma's bacterial cell expression systems for pharmaceutical production | ZymoGenetics gains a non-exclusive license to the technology; Xoma's license terms typically include up-front fees, milestone payments and royalties on sales (6/00) |
Notes: |
|||
# This chart does not include agreements that involve agricultural product development. |
|||
* Private companies are indicated with an asterisk. |
|||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. |
|||
AMEX =American Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange |
|||
